Rituximab: perspective on single agent experience, and future directions in combination trials
- 23 September 2001
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 40 (1) , 3-16
- https://doi.org/10.1016/s1040-8428(01)00130-5
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal AntibodyJapanese Journal of Cancer Research, 1998
- Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignanciesEuropean Journal Of Cancer, 1997
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.The Journal of cell biology, 1993
- Immunotoxins: magic bullets or misguided missiles?Immunology Today, 1993
- Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemiaAmerican Journal of Hematology, 1992
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- Emergence of Idiotype Variants during Treatment of B-Cell Lymphoma with Anti-Idiotype AntibodiesNew England Journal of Medicine, 1985
- Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype AntibodyNew England Journal of Medicine, 1982
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975